Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (13) 13
female (10) 10
index medicus (10) 10
middle aged (10) 10
male (9) 9
adult (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
hematology (6) 6
oncology (6) 6
transplantation (6) 6
aged (5) 5
young adult (5) 5
chemotherapy (4) 4
hematopoietic stem cell transplantation - methods (4) 4
hematopoietic stem cells (4) 4
stem cells (4) 4
analysis (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
bone-marrow-transplantation (3) 3
combined modality therapy (3) 3
free survival (3) 3
hematopoietic stem cell transplantation - adverse effects (3) 3
hematopoietic stem cells - immunology (3) 3
medicine & public health (3) 3
mortality (3) 3
recurrence (3) 3
survival rate (3) 3
t cells (3) 3
transplantation conditioning - methods (3) 3
transplantation, homologous (3) 3
treatment outcome (3) 3
1st complete remission (2) 2
1st-line treatment (2) 2
adolescent (2) 2
age (2) 2
cancer (2) 2
care and treatment (2) 2
cisplatin (2) 2
clinical trials (2) 2
cytarabine - administration & dosage (2) 2
disease-free survival (2) 2
diseases (2) 2
genetic aspects (2) 2
genetics (2) 2
graft vs host disease - etiology (2) 2
graft vs host disease - prevention & control (2) 2
haploidentical hematopoietic cell transplantation (2) 2
haplotypes (2) 2
hematology, oncology and palliative medicine (2) 2
hematopoietic stem cells - cytology (2) 2
immunosuppressive agents - adverse effects (2) 2
incidence (2) 2
internal medicine (2) 2
kaplan-meier estimate (2) 2
leukemia (2) 2
lymphocyte depletion (2) 2
lymphomas (2) 2
multiple myeloma - drug therapy (2) 2
original article · originalarbeit (2) 2
patients (2) 2
prevention (2) 2
relapse (2) 2
retreatment (2) 2
stem cell transplantation (2) 2
stem-cell transplantation (2) 2
survival (2) 2
t-lymphocytes - immunology (2) 2
therapy (2) 2
transplantation conditioning (2) 2
tumors (2) 2
versus-host-disease (2) 2
1-phosphatidylinositol 3-kinase (1) 1
5-fluorouracil, continuous infusional (1) 1
5-ht (1) 1
5-ht3 antagonist (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
[sdv.can] life sciences [q-bio]/cancer (1) 1
[sdv.can]life sciences [q-bio]/cancer (1) 1
abnormalities (1) 1
abridged index medicus (1) 1
activation (1) 1
acute gvhd (1) 1
acute myelogenous leukemia (1) 1
acute myeloid leukaemia (1) 1
acute myeloid-leukemia (1) 1
adenocarcinoma - drug therapy (1) 1
adenocarcinoma - mortality (1) 1
adenocarcinoma - pathology (1) 1
adjuvants, immunologic (1) 1
adult onset still’s disease (1) 1
advanced gastrointestinal cancer (1) 1
akt protein (1) 1
allogene transplantation (1) 1
allogeneic haematopoietic stem cell transplantation (1) 1
allogeneic transplantation (1) 1
allografts (1) 1
aml (1) 1
anakinra (1) 1
analysis of variance (1) 1
anemia, sickle cell - blood (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
by Hermine, Olivier, Prof and Hoster, Eva, PhD and Walewski, Jan, MD and Bosly, André, MD and Stilgenbauer, Stephan, MD and Thieblemont, Catherine, MD and Szymczyk, Michal, MD and Bouabdallah, Reda, MD and Kneba, Michael, Prof and Hallek, Michael, Prof and Salles, Gilles, Prof and Feugier, Pierre, MD and Ribrag, Vincent, MD and Birkmann, Josef, MD and Forstpointner, Roswitha, MD and Haioun, Corinne, MD and Hänel, Mathias, MD and Casasnovas, René Olivier, MD and Finke, Jürgen, MD and Peter, Norma, MD and Bouabdallah, Kamal, MD and Sebban, Catherine, MD and Fischer, Thomas, Prof and Dührsen, Ulrich, Prof and Metzner, Bernd, MD and Maschmeyer, Georg, MD and Kanz, Lothar, Prof and Schmidt, Christian, MD and Delarue, Richard, MD and Brousse, Nicole, MD and Klapper, Wolfram, MD and Macintyre, Elizabeth, Prof and Delfau-Larue, Marie-Hélène, Prof and Pott, Christiane, MD and Hiddemann, Wolfgang, Prof and Unterhalt, Michael, PhD and Dreyling, Martin, Prof and European Mantle Cell Lymphoma and European Mantle Cell Lymphoma Network
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10044, pp. 565 - 575
Summary Background Mantle cell lymphoma is characterised by a poor long-term prognosis. The European Mantle Cell Lymphoma Network aimed to investigate whether... 
Internal Medicine | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | RESPONSE CRITERIA | FREE SURVIVAL | TEMSIROLIMUS | PLUS RITUXIMAB | FOLLOW-UP | CHOP | INDOLENT | Doxorubicin - therapeutic use | Humans | Middle Aged | Lymphoma, Mantle-Cell - drug therapy | Male | Combined Modality Therapy | Cytarabine - adverse effects | Cyclophosphamide - therapeutic use | Cytarabine - administration & dosage | Lymphoma, Mantle-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Immunotherapy | Treatment Failure | Vincristine - therapeutic use | Adult | Female | Immunosuppressive Agents - adverse effects | Hematopoietic Stem Cell Transplantation - methods | Transplantation Conditioning | Immunosuppressive Agents - administration & dosage | Prednisone - therapeutic use | Transplantation | Epidemiology | Stem cells | Tumors | Medical informatics | Clinical trials | Chemotherapy | Lymphomas | Clinical outcomes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial
by Thiel, Eckhard, Prof and Korfel, Agnieszka, MD and Martus, Peter, Prof and Kanz, Lothar, Prof and Griesinger, Frank, MD and Rauch, Michael, MD and Röth, Alexander, MD and Hertenstein, Bernd, MD and von Toll, Theda, MD and Hundsberger, Thomas, MD and Mergenthaler, Hans-Günther, MD and Leithäuser, Malte, MD and Birnbaum, Tobias, MD and Fischer, Lars, MD and Jahnke, Kristoph, MD and Herrlinger, Ulrich, MD and Plasswilm, Ludwig, MD and Nägele, Thomas, MD and Pietsch, Torsten, Prof and Bamberg, Michael, Prof and Weller, Michael, Prof
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 11, pp. 1036 - 1047
Summary Background High-dose methotrexate is the standard of care for patients with newly diagnosed primary CNS lymphoma. The role of whole brain radiotherapy... 
Hematology, Oncology and Palliative Medicine | DEFERRED RADIOTHERAPY | 1ST-LINE TREATMENT | ONCOLOGY-GROUP | COMBINED-MODALITY THERAPY | ONCOLOGY | CONSOLIDATION RADIOTHERAPY | CELL TRANSPLANTATION | INITIAL TREATMENT | CENTRAL-NERVOUS-SYSTEM | CEREBROSPINAL-FLUID | CHEMOTHERAPY | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Lymphoma - mortality | Antimetabolites, Antineoplastic - administration & dosage | Central Nervous System Neoplasms - radiotherapy | Lymphoma - drug therapy | Time Factors | Dose Fractionation | Female | Lymphoma - radiotherapy | Radiotherapy, Adjuvant | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Chi-Square Distribution | Cranial Irradiation - adverse effects | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Methotrexate - administration & dosage | Aged | Central Nervous System Neoplasms - drug therapy | Central Nervous System Neoplasms - mortality | Germany | Chemotherapy | Radiation | Product development | Lymphomas | Methotrexate | Radiotherapy | Biometry | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The Cytogenetic Profile In Lymphoid and Myeloid CML Blast Crisis
by Kalmanti, Lida and Dietz, Christian and Pfirrmann, Markus and Haferlach, Claudia and Göhring, Gudrun and Schlegelberger, Brigitte and Jotterand, Martine and Hehlmann, Rüdiger and Hochhaus, Andreas and Müller, Martin C and Hanfstein, Benjamin and Proetel, Ulrike and Krause, Stefan W and Einsele, Hermann and Dengler, Jolanta and Falge, Christiane and Kanz, Lothar and Neubauer, Andreas and Kneba, Michael and Stegelmann, Frank and Pfreundschuh, Michael and Prof, MD and Waller, Cornelius F and Spiekermann, Karsten and Lauseker, Michael and Hasford, Joerg and Hofmann, Wolf-Karsten and Saussele, Susanne and Fabarius, Alice
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 1487 - 1487
Abstract Introduction In acute leukemias, specific cytogenetic aberrations frequently correlate with myeloid or lymphoid phenotype of blasts and influence risk... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Sequential chemotherapy followed by reduced‐intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT
by Ringdén, Olle and Labopin, Myriam and Schmid, Christoph and Sadeghi, Behnam and Polge, Emmanuelle and Tischer, Johanna and Ganser, Arnold and Michallet, Mauricette and Kanz, Lothar and Schwerdtfeger, Rainer and Nagler, Arnon and Mohty, Mohamad and Acute Leukaemia Working Party of the EBMT and the Acute Leukaemia Working Party of the EBMT
British Journal of Haematology, ISSN 0007-1048, 02/2017, Volume 176, Issue 3, pp. 431 - 439
Summary This study analysed the outcome of 267 patients with relapse/refractory acute myeloid leukaemia (AML) who received sequential chemotherapy including... 
sequential chemotherapy | reduced intensity conditioning | acute myeloid leukaemia | allogeneic haematopoietic stem cell transplantation | CYTOSINE-ARABINOSIDE | FREE SURVIVAL | BONE-MARROW-TRANSPLANTATION | 1ST COMPLETE REMISSION | MYELODYSPLASTIC SYNDROME | MATCHED UNRELATED DONORS | GRAFT-VERSUS-LEUKEMIA | HIGH-RISK | HLA-IDENTICAL SIBLINGS | HOST-DISEASE | HEMATOLOGY | Recurrence | Humans | Middle Aged | Male | Hematopoietic Stem Cell Transplantation - mortality | Leukemia, Myeloid, Acute - complications | Young Adult | Allografts | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Surveys and Questionnaires | Retrospective Studies | Transplantation Conditioning - methods | Graft vs Host Disease - etiology | Leukemia, Myeloid, Acute - therapy | Antibodies - therapeutic use | Survival Rate | Treatment Outcome | Combined Modality Therapy | Leukemia, Myeloid, Acute - mortality | Antibodies - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | T-Lymphocytes - immunology | Aged | Hematopoietic Stem Cell Transplantation - methods | Salvage Therapy - methods | Surveys | Viral antibodies | Chemotherapy | Relapse | Stem cells | Antibodies | Transplantation | T cells | Hematopoietic stem cells | Diseases | Cancer | Graft-versus-host reaction | Immunoglobulins | Transplants & implants | Leukemia | Stem cell transplantation | Transplants | Lymphocytes T | Multivariate analysis | Patients | Survival | Incidence | Cytarabine | Fludarabine | Donors | Conditioning
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients
by Rittig, Susanne M and Haentschel, Maik and Weimer, Katrin J and Heine, Annkristin and Muller, Martin R and Brugger, Wolfram and Horger, Marius S and Maksimovic, Olga and Stenzl, Arnulf and Hoerr, Ingmar and Rammensee, Hans-Georg and Holderried, Tobias AW and Kanz, Lothar and Pascolo, Steve and Brossart, Peter
Molecular Therapy, ISSN 1525-0016, 05/2011, Volume 19, Issue 5, pp. 990 - 999
The aim of this phase I/II nonrandomized trial was to assess feasibility, safety as well as immunological and clinical responses of a mRNA-based vaccination in... 
CANCER PATIENTS | MEDICINE, RESEARCH & EXPERIMENTAL | DIRECT-INJECTION | RENAL-CELL CARCINOMA | CYTOTOXIC T-LYMPHOCYTES | TRANSFECTED DENDRITIC CELLS | MESSENGER-RNA | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | IN-VIVO | GENETICS & HEREDITY | TUMOR-DERIVED RNA | ANTIGEN | EPITOPES | Antigens, Neoplasm - genetics | Genetic Therapy | Enzyme-Linked Immunosorbent Assay | Adjuvants, Immunologic | Antigens, Neoplasm - immunology | Cancer Vaccines - administration & dosage | Humans | Middle Aged | RNA, Messenger - genetics | Carcinoma, Renal Cell - genetics | Male | Granulocyte-Macrophage Colony-Stimulating Factor - genetics | CD4-Positive T-Lymphocytes - immunology | Cancer Vaccines - genetics | Cancer Vaccines - immunology | Granulocyte-Macrophage Colony-Stimulating Factor - immunology | RNA, Messenger - administration & dosage | Carcinoma, Renal Cell - therapy | Female | Aged | CD8-Positive T-Lymphocytes - immunology | RNA, Messenger - therapeutic use | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts
by Michaelis, Sebastian U and Mezger, Markus and Bornhäuser, Martin and Trenschel, Rudolf and Stuhler, Gernot and Federmann, Birgit and Oevermann, Lena and Kanz, Lothar and Handgretinger, Rupert and Bethge, Wolfgang A
Annals of Hematology, ISSN 0939-5555, 9/2014, Volume 93, Issue 9, pp. 1579 - 1586
Natural killer (NK)-cell alloreactivity after allogeneic hematopoietic cell transplantation (HCT) is influenced by the interaction of killer-cell... 
Haploidentical hematopoietic cell transplantation | Oncology | KIR haplotype | Medicine & Public Health | Hematology | KIR-ligand model | NATURAL-KILLER-CELLS | IMMUNOGLOBULIN-LIKE RECEPTORS | FREE SURVIVAL | ACUTE GVHD | ACUTE MYELOGENOUS LEUKEMIA | HEMATOPOIETIC TRANSPLANTS | GROUP-A | STEM-CELL TRANSPLANTATION | HLA | HEMATOLOGY | T-CELLS | Haplotypes | Recurrence | Humans | Middle Aged | Blood Group Incompatibility - complications | Male | Antigens, CD19 - genetics | Transplantation, Homologous | Incidence | Young Adult | Hematopoietic Stem Cells - immunology | CD3 Complex - genetics | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Transplantation Conditioning - adverse effects | Transplantation Conditioning - methods | Receptors, KIR - genetics | Cell Separation | Histocompatibility Testing | Hematopoietic Stem Cells - metabolism | Histocompatibility Antigens Class I - genetics | CD3 Complex - metabolism | Hematologic Neoplasms - surgery | Blood Group Incompatibility - genetics | Hematopoietic Stem Cells - cytology | Antigens, CD19 - metabolism | Hematologic Neoplasms - genetics | Histocompatibility antigens | Analysis | Mortality | HLA histocompatibility antigens | Genetic aspects | Transplantation | Hematopoietic stem cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial
by Einsele, Hermann and Engelhardt, Monika and Tapprich, Christoph and Müller, Jürgen and Liebisch, Peter and Langer, Christian and Kropff, Martin and Mügge, Lars O and Jung, Wolfram and Wolf, Hans‐Heinrich and Metzner, Bernd and Hart, Christina and Gramatzki, Martin and Hertenstein, Bernd and Pfreundschuh, Michael and Rösler, Wolf and Fischer, Thomas and Maschmeyer, Georg and Kanz, Lothar and Hess, Georg and Jäger, Elke and Bentz, Martin and Dürk, Heinz A and Salwender, Hans and Hebart, Holger and Straka, Christian and Knop, Stefan
British Journal of Haematology, ISSN 0007-1048, 11/2017, Volume 179, Issue 4, pp. 586 - 597
Summary We assessed the safety and efficacy of bortezomib, cyclophosphamide and dexamethasone (VCD) induction therapy in previously untreated multiple myeloma... 
dexamethasone | cyclophosphamide | multiple myeloma | induction therapy | bortezomib | HIGH-RISK CYTOGENETICS | MULTIPARAMETER FLOW-CYTOMETRY | INDUCED PERIPHERAL NEUROPATHY | NEWLY-DIAGNOSED PATIENTS | PLUS DEXAMETHASONE | HIGH-DOSE THERAPY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | HOVON-65/GMMG-HD4 TRIAL | CHROMOSOMAL-ABERRATIONS | Risk Assessment - methods | Cyclophosphamide - administration & dosage | Dexamethasone - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Induction Chemotherapy - methods | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Transplantation, Autologous | Consolidation Chemotherapy | Stem Cell Transplantation | Young Adult | Multiple Myeloma - drug therapy | Bortezomib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Cytogenetics | Adult | Female | Cyclophosphamide | Dexamethasone | Bortezomib | Analysis | Multiple myeloma | Stem cells | Clinical trials | Transplantation | Steroids | Thrombocytopenia | Autografts | Therapy | Risk groups | Abnormalities | Stem cell transplantation | Risk | Patients | Survival | Consolidation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Anti-thymocyte globulin-induced hyperbilirubinemia in patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation
by Ecsedi, Matyas and Schmohl, Jörg and Zeiser, Robert and Drexler, Beatrice and Halter, Jörg and Medinger, Michael and Duyster, Justus and Kanz, Lothar and Passweg, Jakob and Finke, Jürgen and Bethge, Wolfgang and Lengerke, Claudia
Annals of Hematology, ISSN 0939-5555, 10/2016, Volume 95, Issue 10, pp. 1627 - 1636
Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only curative treatment option for myelofibrosis (MF) despite the emergence of novel... 
Anti-thymocyte globulin | Hematopoietic cell transplantation | Myelofibrosis | Medicine & Public Health | Hematology | Oncology | Hepatic toxicity | Bilirubin | BONE-MARROW-TRANSPLANTATION | ANTITHYMOCYTE GLOBULIN | MECHANISMS | TOXICITY | VERSUS-HOST-DISEASE | IMPACT | HEPATIC VENOOCCLUSIVE DISEASE | HEMATOLOGY | AGE | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Male | Liver - physiopathology | Case-Control Studies | Transplantation, Homologous | Iron Overload - blood | Iron Overload - etiology | Primary Myelofibrosis - blood | Young Adult | Liver - drug effects | Antilymphocyte Serum - therapeutic use | Adult | Female | Transplantation Conditioning - methods | Hyperbilirubinemia - etiology | Antilymphocyte Serum - adverse effects | Graft Rejection - prevention & control | Hematopoietic Stem Cell Transplantation | Transfusion Reaction | Hyperbilirubinemia - immunology | Graft vs Host Disease - prevention & control | Immunosuppressive Agents - adverse effects | T-Lymphocytes - immunology | Aged | Primary Myelofibrosis - therapy | Care and treatment | Hyperbilirubinemia | Analysis | Mortality | Liver | Transplantation | T cells | Hematopoietic stem cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: A combination of extremely rare diseases with probable further implications
by Löffler, Markus W and Steinhilber, Julia and Hilke, Franz J and Haen, Sebastian P and Bösmüller, Hans and Montes-Mojarro, Ivonne-Aidee and Bonzheim, Irina and Stäbler, Antje and Faust, Ulrike and Grasshoff, Ute and Königsrainer, Ingmar and Rammensee, Hans-Georg and Kanz, Lothar and Königsrainer, Alfred and Beckert, Stefan and Riess, Olaf and Schroeder, Christopher
BMC Medical Genetics, ISSN 1471-2350, 08/2018, Volume 19, Issue 1, pp. 144 - 7
The PTEN-hamartoma-tumor-syndrome (PHTS) is caused by germline mutations in Phosphatase and Tensin homolog (PTEN) and predisposes to the development of several... 
Malignant Peritoneal Mesothelioma | Hereditary Tumor Syndrome | PTEN-Hamartoma-Tumor-Syndrome | Verrucous Carcinoma | Case Report | Lung Neoplasms - genetics | PTEN Phosphohydrolase - genetics | Humans | Mesothelioma - genetics | Rare Diseases | Carcinoma, Verrucous - genetics | Germ-Line Mutation - genetics | Mouth Neoplasms - genetics | Case studies | Gene mutations | Tumor suppressor genes | Mesothelioma | Genetic aspects | Health aspects | Mouth cancer | Immunohistochemistry | Asbestos | Disease | Genes | AKT protein | Phosphatase | Kinases | Occupational exposure | Thyroid carcinoma | Clonal deletion | Surgery | Age | Tensin | Medical screening | 1-Phosphatidylinositol 3-kinase | Chemotherapy | Thyroid cancer | Molecular modelling | Medical prognosis | Mutation | Neoplasia | PTEN protein | Peritoneum | Tumors | Apoptosis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation
by Haen, Sebastian P and Groh, Christiane and Schumm, Michael and Backert, Linus and Löffler, Markus W and Federmann, Birgit and Faul, Christoph and Dörfel, Daniela and Vogel, Wichard and Handgretinger, Rupert and Kanz, Lothar and Bethge, Wolfgang A
Annals of Hematology, ISSN 0939-5555, 5/2017, Volume 96, Issue 5, pp. 817 - 827
Disease relapse after one or more allogeneic hematopoietic cell transplantations (HCT) represents a therapeutic challenge with all options bearing a... 
Haploidentical hematopoietic cell transplantation | Graft versus host disease | Relapse | Medicine & Public Health | Hematology | Oncology | Salvage therapy | AML | BONE-MARROW-TRANSPLANTATION | UNRELATED DONORS | PREVENTION | ACUTE MYELOID-LEUKEMIA | 1ST COMPLETE REMISSION | VERSUS-HOST-DISEASE | PREDICTION | INTERNATIONAL WORKSHOP | HEMATOLOGY | HEMATOLOGIC MALIGNANCIES | Haplotypes | Recurrence | Humans | Middle Aged | Salvage Therapy | Male | Lymphocyte Depletion | Transplantation, Homologous | Young Adult | Hematopoietic Stem Cells - immunology | Leukemia - complications | Hematopoietic Stem Cell Transplantation - adverse effects | Adult | Female | Graft vs Host Disease - etiology | T-Lymphocytes | Mortality | Kaplan-Meier Estimate | Leukemia - therapy | Graft Survival | Treatment Outcome | Combined Modality Therapy | Transplantation Chimera | Retreatment | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Leukemia - diagnosis | Graft vs Host Disease - prevention & control | Hematopoietic Stem Cell Transplantation - methods | Tissue Donors | Transplantation Conditioning | Leukemia - mortality | Complications and side effects | Care and treatment | Leukemia | Transplantation | T cells | Hematopoietic stem cells | Diseases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Classical Hodgkin Lymphoma as De Novo B-Cell Malignancy After Treatment of Multiple Myeloma in the Pre-Lenalidomide Era
by Zago, Manola and Adam, Patrick and Goldschmidt, Hartmut and Fend, Falko and Kanz, Lothar and Weisel, Katja
Clinical Lymphoma, Myeloma & Leukemia, ISSN 2152-2650, 2014, Volume 14, Issue 1, pp. e7 - e11
During the past decade, introduction of the novel agents in treatment of multiple myeloma disease resulted in a significant improvement in response and an... 
Hematology, Oncology and Palliative Medicine | EBV | High-dose mephalan | Thalidomide | Secondary primary malignancy | B-cell clonality | Thalidomide - adverse effects | Hodgkin Disease - pathology | Humans | Middle Aged | Hodgkin Disease - etiology | B-Lymphocytes - drug effects | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - pathology | Female | Immunologic Factors - adverse effects | B-Lymphocytes - pathology | Thalidomide - therapeutic use | Immunologic Factors - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Enhanced Erythrocyte Apoptosis in Sickle Cell Anemia, Thalassemia and Glucose-6-Phosphate Dehydrogenase Deficiency
by Lang, Karl and Roll, Benjamin and Myssina, Svetlana and Schittenhelm, Markus and Scheel-Walter, Hans-Gerhard and Kanz, Lothar and Fritz, Jasmin and Lang, Florian and Huber, Stephan and Wieder, Thomas
Cellular Physiology and Biochemistry, ISSN 1015-8987, 2002, Volume 12, Issue 5-6, pp. 365 - 372
Erythrocyte diseases such as sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency decrease the erythrocyte life span, an effect... 
Original Paper | Oxidation | tBOOH | Cell volume | Osmotic cell shrinkage | Annexin | Glucose depletion | cell volume | ACTIVATION | PHAGOCYTOSIS | PHYSIOLOGY | osmotic cell shrinkage | RAT HEPATOCYTES | MACROPHAGES | VOLUME | oxidation | CELL BIOLOGY | SHRINKAGE | HYPERTONICITY | annexin | glucose depletion | PHOSPHATIDYLSERINE EXPOSURE | CHLORIDE CONDUCTANCE | NA+ CONDUCTANCE | Osmotic Pressure | Thalassemia - blood | Confidence Intervals | Glucosephosphate Dehydrogenase Deficiency - blood | Annexins - metabolism | Erythrocytes, Abnormal - drug effects | Humans | Oxidative Stress - physiology | Erythrocyte Membrane - metabolism | Hydrogen Peroxide - pharmacology | Erythrocytes, Abnormal - metabolism | Hydrogen Peroxide - chemistry | Glucose - deficiency | Erythrocytes, Abnormal - pathology | Flow Cytometry | Analysis of Variance | Ionomycin - pharmacology | Anemia, Sickle Cell - blood | Apoptosis - physiology | Phosphatidylserines - blood
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights